Related Experiment Video
Updated: May 29, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
The clinical development of FLT3 inhibitors in acute myeloid leukemia
1Cardiff University, University Hospital of Wales, Department of Haematology, Heath Park, Cardiff, CF14 4XW, UK. knappers@cf.ac.uk
Introduction:
Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at high frequency in acute myeloid leukemia (AML), being detected in > 30% of patients at diagnosis and carrying a profound negative prognostic impact. The development of effective small molecule inhibitors of FLT3 has been the focus of an intensive international research effort in recent years.
Areas Covered:
The published results of the first decade of clinical trials of FLT3-targeted tyrosine kinase inhibitors are critically reviewed. Over this period, a first generation of compounds has followed an orderly progression from monotherapy studies through combination with chemotherapy and into advanced stage international trials in both relapsed and newly-diagnosed AML. Correlative laboratory studies performed alongside several of these studies have been highly illuminating, demonstrating close correlations between clinical activity and effective inhibition of FLT3, and highlighting potential drug resistance mechanisms.
Expert Opinion:
Clinical responses to several of the early multi-targeted agents were hindered by unfavorable pharmacokinetics and lack of potency. Newer, more potent FLT3 inhibitors such as sorafenib and AC220 possess the ability to achieve more sustained in vivo inhibition of FLT3 and have shown highly promising activity in early clinical studies. As these agents enter advanced stage trials, they carry the potential to make a major clinical impact in this disease. In future, FLT3 inhibitors may be effectively used in combination with other molecularly targeted agents.
Insights
Activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are common in acute myeloid leukemia (AML). Newer FLT3 inhibitors show promise for improving patient outcomes by targeting these mutations.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene are prevalent in acute myeloid leukemia (AML), affecting over 30% of patients.
- These FLT3 mutations are associated with a poor prognosis in AML.
- Targeting FLT3 with small molecule inhibitors is a key research area in AML treatment.
Purpose of the Study:
- To critically review the clinical trial outcomes of FLT3-targeted tyrosine kinase inhibitors over the past decade.
- To evaluate the progression of FLT3 inhibitor development from early-phase monotherapy to combination treatments in AML.
- To analyze correlative laboratory studies assessing FLT3 inhibition and resistance mechanisms.
Main Methods:
- Systematic review of published clinical trial data for FLT3 inhibitors in AML.
- Analysis of correlative laboratory studies linked to clinical trials.
- Evaluation of drug pharmacokinetics, potency, and in vivo inhibition.
Main Results:
- First-generation FLT3 inhibitors showed limited efficacy due to pharmacokinetic issues and insufficient potency.
- Newer inhibitors, such as sorafenib and AC220, demonstrate enhanced potency and sustained in vivo FLT3 inhibition.
- Early clinical studies of potent FLT3 inhibitors indicate highly promising activity in AML.
Conclusions:
- Advanced FLT3 inhibitors hold significant potential for clinical impact in AML treatment.
- Future strategies may involve combining FLT3 inhibitors with other molecularly targeted agents.
- Ongoing research focuses on overcoming limitations of earlier FLT3-targeted therapies.